Abemaciclib (NCT04040205)

Name: Abemaciclib trial for Chondrosarcoma (NCT04040205)
Uploaded: 2026-10-31T21:02:13.255Z
Duration: 1 min 29 s
Description: Abemaciclib trial for Chondrosarcoma (NCT04040205). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04040205.

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration: a one-minute explainerNCT040402051 min

Abemaciclib trial for Chondrosarcoma (NCT04040205). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with unresectable advanced or metastatic soft-tissue sarcoma, chondrosarcoma, chordoma, or osteosarcoma, selected CDK-pathway alterations, and intact Rb protein. Well-differentiated and dedifferentiated liposarcoma are excluded. Prior-treatment requirements depend on subtype; previous CDK4/6 inhibitors are excluded.

The idea: abemaciclib blocks CDK4/6, a pathway involved in cell division. Patients take 200 milligrams by mouth twice daily until progression or another stopping criterion. Researchers measure progression-free survival at twelve weeks.

This phase 2 study plans 44 patients. John Charlson leads at the Medical College of Wisconsin in Milwaukee; four US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.